

July 23, 2020

Ref : APS/MSCDA/512/2020

**ALL THE OFFICE BEARERS / ZONAL OFFICE BEARERS &
DISTRICT PRESIDENTS/SECRETARIES
OF THE M.S.C.D.A.**

Subject : DCGI Circular to all state Drug Controller No. ED/Mis-272/2020-1 dated 06.07.2020


Dear sir,

Please find attached letters received from AIOCD vide ref no.APS/AIOCD/633/2020 dt. July 22, 2020 alongwith Drugs Controller General (I) (DCGI) letter ref no. ED/Misc-273/2020-1 dt.06.07.2020 advising immediate enforcement to stop the sale of COVID – 19 drug **Remedesivir above MRP**.

Kindly circulate the same amongst all your members for their information and necessary action.

Thanking you.

Yours faithfully
For The MSCDA



(Anil Navandar)
Hon Gen. Secretary



THE ALL INDIA ORGANISATION OF CHEMISTS & DRUGGISTS®

201, Safalya Bldg., 2nd Floor, Opp. Jaigopal Industrial Estate, Baburao Parulekar Marg, Dadar (W), Mumbai 400 028.
Tel.: 2430 6889 / 2430 6874 / 6145 2929 • Fax : 2430 6973 / 6145 2925 • Visit us on : www.aiocd.net

President :

J. S. SHINDE

Email: aiocd@aiocd.com

jagannath.shinde@aiocd.com

Hon. Gen- Secretary :

RAJIV SINGHAL

M/s. Shree Radhey Trade Logistics,
Prabhu Kripa 120, S. R. Compound,
Lasudia, Indore - 452 010, M.P.

Tel. : 0731 - 4002350 Mob.: 9425056394

Email : gsrajiv.singhal@aiocd.com

July 22, 2020

Ref : APS/AIOCD/633/2020

**ALL OFFICE BEARERS / PRESIDENTS / SECRETARIES AND
EXECUTIVE COMMITTEE MEMBERS OF AIOCD**

Reg: DCGI Circular to all State Drug Controller No. ED/Mis-272/2020-1 Dated: 6-07-2020

Dear Sir,

With reference to above circular, enclosed with this, sent by DCGI to all state Drug Controllers advising immediate enforcement on the sale of Covid-19 drug Remdesivir above MRP.

All of you know very well, that many Covid Drugs like Faviflu, Tocilizumab, and Remdesivir have been launched in the market to treat Covid-19 patients in India in recent past.

All members of AIOCD are co operating distribution of such drugs to companies those are supplying through stokiest members.

Media report claims that Remdesivir is being sold to patients with higher price over & above the MRP fixed by the Company/ Govt. We do not have knowledge of any such activity, still AIOCD condemns these types of activities if any.

You are requested to advice all our members to be alert & ensure strict compliance of sale process. Overcharging or involvement in such activity also attracts prosecution by administrators. Let's serve the needy patients in this crucial situation with caution. Also instruct to your members not to purchase any product /drug from any unknown source. This may lead to spurious/ mis branded medicines also .

Till this date all our members have kept our reputation at a very high level & we are known as Jan Swasthy Rakshak by serving our country.

You are requested to take immediate action and inform all members that if any of the members found guilty , involved in unethical activity , Association shall not protect such member.

Please circulate this to all your Stockists/ Retailer members immediately.

Thanking You,

For The All India Organisation of Chemists & Druggists

(J. S. Shinde)
President

(Rajiv Singhal)
Hon Gen. Secretary

Encl : a/a

File No. ED/Misc.-273/2020-1
Government of India
Ministry of Health & Family Welfare
Directorate General of Health Services
Central Drugs Standard Control Organization
(Enforcement Division)

FDA Bhawan, Kotla Road
New Delhi-110002
E-mail: dcj@nic.in
Dated: - 5/7/2020

To,

1. All States/UT Drugs Controller.

Subject: Immediate enforcement needed to stop the sale of COVID-19 drug Remdesivir above MRP-reg.

Sir,

Considering the emergency and unmet medical need for Covid-19 disease, CDSCO has approved Restricted Emergency Use of Remdesivir injectable formulation for treatment of patients with severe Covid-19 infection subject to various conditions and restrictions.

Initially, Remdesivir formulation of the innovator was approved on 01.06.2020 for import and marketing the drug in the country. However, the importer is yet to import the drug after taking import licence from CDSCO. Subsequently, CDSCO has granted permission to manufacture and market the drug to M/s Cipla, M/s Hetro and M/s Mylan Laboratory for same indication, conditions and restrictions.

In this context, this office has received a letter from M/s Local circles, through MoHFW, raising concerns regarding black marketing and over pricing of the drug Remdesivir by certain unscrupulous persons. (copy enclosed)

In view of above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent the black-marketing and sale of the drug Remdesivir Injection above MRP.

Action taken in the matter may please be intimated to this office at the earliest.

Yours faithfully



(Dr. V. G. Somani)
Drugs Controller General (I)

Encls: As above

Copy to:

1. All Zonal and Sub-zonal offices of CDSCO to coordinate with SLA in the matter

Copy for information to:

1. Chairman, NPPA, 3rd/5th Floor, YMCA Cultural Center Building 1, Jai Singh Road, New Delhi, 110001 (chairman.nppa@nic.in)
2. OSD, MoHFW, 243-A, Nirman Bhawan, New Delhi -110011 (osd-mohfw@gov.in)
3. PS to JS(R)